INTRODUCTION

Cross sensitivity is defined as sensitivity to one substance that renders an individual sensitive to other substances of similar chemical structure. Fluoroquinolones have been used for more than 30 years to treat various illnesses such as urinary and respiratory tract infections and are well tolerated. Recently, utilization of fluoroquinolones had led to severe allergic reactions and cross sensitivity reactions. In the last years, immediate reactions to quinolone antibiotics have been observed with increasing frequency, mainly urticaria, angioedema, and shock.

Fluoroquinolones are classified into two groups based on antimicrobial spectrum and pharmacology. Older group: Ciprofloxacin, Norfloxacin and ofloxacin. Newer group: delafloxacin, gemifloxacin, levofloxacin and moxifloxacin. Ciprofloxacin and Norfloxacin are the most common drugs causing hypersensitivity reactions, while levofloxacin is the least common with incidence of 1 per million population.

Ciprofloxacin (C_{18}H_{18}FN_{3}O_{3})

Ciprofloxacin is 1-cyclopropyl-6-fluro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid. Ciprofloxacin is a member of the antibiotic class Quinolones. The presence of a fluorine group at position 6 of the molecule places it into a subclass called the Fluoroquinolones. The bactericidal action of Ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. It is a broad spectrum antibiotic that is widely used in clinical practice for many common afflictions including urinary tract and respiratory tract infections. It is effective against many aerobic Gram-negative organisms including several Streptococcus, Staphylococcus strains and several Gram-positive organisms including Escherichia coli. It is well absorbed from GIT with 70% bioavailability and follows hepatic metabolism. 40-50% of the drug is eliminated through urine with a half-life period of 4 hours and renal clearance of about 300ml/min. Ciprofloxacin is one of the most commonly used antibacterial agents with relatively few side effects. Serious adverse reactions reported with Ciprofloxacin are rare with an incidence of 0.6. A few cases of Ciprofloxacin-induced photosensitivity, hypersensitivity, anaphylaxis, vasculitis, erythema multiforme and Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported so far. Frequently reported immediate hypersensitive reactions are urticaria, anaphylactic shock, rashes and erythema. Delayed type of reactions includes presumably IgE or T cell mediated reactions in about 2-3% of population.

ABSTRACT

A 30 years old male patient was admitted to the dermatology department of Sagar Hospitals with chief complaints of lesions over the hands, lips and at the back of the body and also mild pedal edema noted on 2nd day after the patient had administered Tab parecamol& Tab Ciprofloxacin for the treatment of febrile illness. The Patient had a history of the same reaction twice for the Tab Norfloxacin but never experienced this Adverse Drug Reaction (ADR) to Ciprofloxacin before using Norfloxacin. Upon general examination the patient was treated with Tab Hydralazine, Tab Prednisolone and Calamine lotion after the withdrawal of drug Ciprofloxacin. Dechallenge of Ciprofloxacin showed that there was an improvement in his symptoms indicating drug induced vasculitis. The causality assessment was done by using the Naranjo’s adverse drug reaction probability scale and the score was 9 indicating highly probable relationship between the ADR and the drug, moderate in severity according to Hartwig severity assessment scale. From dechallenge and rechallenge information the patient was concluded to be allergic to Ciprofloxacin and Norfloxacin. In conclusion patient may need to avoid the class of fluoroquinolones since there is a cross reaction to Norfloxacin. Physicians and other healthcare professionals should maintain a high index of suspicion to closely monitor the cases of cutaneous vasculitits due to Ciprofloxacin and Norfloxacin since these drugs are commonly prescribed and well tolerated. Furthermore, this ADR can be prevented in future only by providing the awareness, counseling and also by issuing an ADR alert card to the patient.

Keywords: Cutaneous Vasculitis, Ciprofloxacin, Norfloxacin, Cross Reaction
Structure of Norfloxacin

Norfloxacin is 1-ethyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-
pirazinyl)-3 quinolone carboxylic acid. It is a synthetic, broad-
spectrum bactericidal agent which inhibits bacterial
deoxyribonucleic acid synthesis. The fluorine atom at the 6
position provides increased potency against gram-negative
organisms and the piperazine moiety at 7β position is responsible
for antipseudomonal activity. It is widely used for the treatment
of infections caused by micro-organisms susceptible to
Norfloxacin, including urinary tract infections (uncomplicated and
complicated) and gastrointestinal infections (e.g. shigellosis, traveler’s diarrhoea). Norfloxacin absorption is rapid and is
eliminated through metabolism, biliary excretion, and renal
excretion. Renal excretion occurs by both glomerular filtration
and tubular secretion as evidenced by the high rate of renal
clearance (approximately 275 ml/min). Frequently reported
unwanted reactions were swelling or tearing of (rupture) a tendon, permanent nerve damage, headache with chest pain and severe
dizziness, fainting, fast or pounding heartbeats, dark urine, clay-
colored stools, muscle weakness, diarrhea depression, confusion, hallucination, seizure. Drug induced skin reactions are common,
accounting for 30% for all reported adverse drug reactions. Some
types of drug reaction can cause systemic as well as skin
involvement, affecting the hepatic, hematological and lymphatic
systems.16

Some drugs have the ability to alter the skin and its associated
structures (hair and nails) function among which vasculitis is the
most commonly characterized skin inflammation in vessel walls
and clinically palpable purpuric lesions most commonly found on
the lower limbs. Cutaneous vasculitis without other organ
involvement is the rule, but systemic involvement, such as renal,
can occasionally occur. Drugs are the cause of approximately 10%
of cutaneous vasculitis cases and should be considered in
any patient with small vessel vasculitis. 17

Here there is a case of cutaneous vasculitis associated with
Ciprofloxacin administration which was a cross sensitivity
reaction to Norfloxacin.

CASE REPORT

A 30 years old male patient was admitted to the Dermatology
Department of Sagar Hospitals with chief complaints of lesions
over the hands, lips and at the back of the body and also mild
pedal edema on 2nd day (Figure 1 & Figure 2) after the patient had
administered Tab paracetamol & Tab Ciprofloxacin for the
treatment of febrile illness and generalized weakness. Upon
physical and general examination, patient was conscious &
oriented, febrile; with mild pedal edema; RR 22cpm; Pulse Rate-
85 bpm; B.P.-125/80mmHg; HB-11.5gm/dl; WBC-
12500cell/cumm; ESR-30mm/hr. On systemic examination,
CVS-S1 & S2 (+), RS-NVBS. The patient was treated with Tab
Cetrizine10mg, Tab Prednisolone 20mg and Calamine lotion
after the withdrawal of the drug Ciprofloxacin. Patient had a
history of the same reaction, twice for Tab Norfloxacin but never
experienced this Adverse Drug Reaction (ADR) to Ciprofloxacin
before using Norfloxacin. Based on the above information here
we have suspected it as a possible cross sensitivity reaction/ADR
of Ciprofloxacin as shown in Fig (3 and 4). Patient was further
referred to General Medicine to confirm the ADR/Cross
sensitivity reaction. Upon analysis it is found that the patient had
suffered from cutaneous vasculitis due to the administration of
Ciprofloxacin. Certain literature also supports that 2% chances of
hypersensitivity reactions are associated with this drug. In order
to confirm the relation between the drug and the following event
De challenge (withdrawal of the drug) was performed after which
the reaction was subsided.

Causality and severity Assessment: The causality assessment
was done using the Naranjo’s adverse drug reaction probability
scale and the score was 9 indicating highly probable relationship
between the ADR and drug. The reaction was moderate in
severity according to Hart-wig severity assessment scale.

RESULTS AND DISCUSSION

In medicine, a case report is a detailed report of the
symptoms, signs, diagnosis, treatment, and follow-up of an
individual patient. Case reports may contain a socio demographic
profile of the patient, but usually describe an unusual or novel
occurrence. Here case report was discussed on cross sensitivity
between Ciprofloxacin and Norfloxacin.

Patient had a history of first hypersensitivity reaction (within 8
hours) to Norfloxacin and was not allergic to Ciprofloxacin. In
this case report, patient had experienced immediate
hypersensitivity reaction (within 2 hours) to Ciprofloxacin after
exposure to Norfloxacin, only which proved the cross sensitivity
between Ciprofloxacin and Norfloxacin.

All fluoroquinolones have similar core structure (4-oxo-1, 4-
dihydroquinoline ring) with fluoride atom attached at position 6
except, first generation fluoroquinolones-quinolone and nalidixic
acid. Norfloxacin, a second generation fluoroquinolone, is the
result of replacement at C-7 methyl side chain with piperazine
group, while replacement of N-1 ethyl group of Norfloxacin with
cyclopropyl group generates Ciprofloxacin.Ciprofloxacin and
Norfloxacin have similar core structure this is may be the reason
for cross-sensitivity in this reaction. This patient may have similar
hypersensitivity reactions to other fluoroquinolones. In such case
it is advisable to avoid fluoroquinolones and shift to other class
of antimicrobials to treat infectious conditions.18Detection of IgE antibodies in blood and skin tests were helpful to identify such
cross reactions and prevent the same.19 54.5% immediate type of
reactions to fluoroquinolones are IgE mediated and occurs due to
binding of IgE to 7th position of core structure of fluoroquinolones.20

Additionally, the results of previous In vitro study showed that
Ciprofloxacin and Norfloxacin could stimulate histamine
release.21 To our knowledge, there was only one case report on
cross sensitivity between Ciprofloxacin and Norfloxacin.22 But
there were many case reports on cross immediate hypersensitivity
reaction between Ciprofloxacin and levofloxacin.23,24

CONCLUSION

Subsequently the patient was diagnosed to have Cutaneous
Vasculitis and further confirmed to have been allergic to
Ciprofloxacin and Norfloxacin (probably most Fluroquinolones). These drugs are commonly prescribed and
well tolerated. Furthermore, this ADR can be prevented in future,
only by providing the awareness, counseling and also by issuing
an ADR alert card to the patient. Physicians and other healthcare
professionals should maintain a high index of suspicion to closely
monitor the cases of cutaneous vasculitis due to Ciprofloxacin
and Norfloxacin.
ACKNOWLEDGEMENTS

Authors are thankful to the head of Sagar Hospital, Bengaluru, India for providing support and facilitating the data collection.

REFERENCES

1. Mosby's Medical Dictionary Myers T, editor. 8th ed. New York: Mosby Elsevier; 2009. p. 23-5.
2. Van Bambeker F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin. Drug safety. 2009 May;32(5):359-78.
3. Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F, Salas M, Rondon C, Canto MG, Blanca M. Drug Hypersensitivity Reactions: Response Patterns, Drug Involvement, and Temporal Variations in a Large Series of Patients. Journal of Investigational Allergology and Clinical Immunology. 2012 Jan 1;22(5):363.
4. Manfredi M, Severino M, Testi S, Macchia D, Ermini G, Pichler WJ, Campi P. Detection of specific IgE to quinolones. Journal of allergy and clinical Immunology. 2004 Jan 1;113(1):155-60.
5. Brian J. Werth (2018) (Accessed: 2nd February 2019).
6. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 2001;47(Suppl. 3):9-14.
7. Drusano GL, Standiford HC, Piaiseacci K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrobial agents and chemotherapy. 1986 Sep 1;30(3):444-6.
8. Pharma Tips (2011) Ciprofloxacin Drug - Medicinal Chemistry & Uses, Available at: http://www.pharmatips.in /Articles/Chemistry/Medicinal-Chemistry/Ciprofloxacin-Drug.aspx (Accessed: 2nd January 2019).
9. Pharma Tips (2011) Ciprofloxacin Drug - Medicinal Chemistry & Uses, Available at: http://www.pharmatips.in /Articles/Chemistry/Medicinal-Chemistry/Ciprofloxacin-Drug.aspx (Accessed: 2nd January 2019).
10. Shilpashree HS, Sarapur S. Ciprofloxacin-induced erythema multiforme. Journal of pharmacology & pharmacotherapeutics. 2012 Oct;3(4):339.
11. Kumar S, Jeevanti R, Manjunath S, Wali VK. A case of Ciprofloxacin induced erythema multiform. Indian Journal of Pharmacology. 2008;40(1):45-6.
12. Lobera T, Audicona MT, Alarcon E, Longo N, Navarro B, Munoz D. Allergy to quinolones: low cross-reactivity to levofloxacin. J InvestigAllergolClinImmunol. 2010 Jan 1;20(7):607-11.
13. Gonzalez I, Lobera T, Blasco A, delPozo MD. Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. J InvestigAllergolClinImmunol. 2005 Jan 1;15(2):146-9.
14. BjornssonBjörnsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. The American journal of gastroenterology. 2000 Dec;95(12):3662.
15. Everyday Health (2017) What Is Norfloxacin, Available at: https://www.everydayhealth.com/drugs/Norfloxacin (Accessed: 2nd February 2019).
16. S. Walsh and D.creamer. Drug induced skin disorders. In: Roger Walker Cate Whittlesea, editor. Clinical pharmacy and therapeutics, 5th ed. Edinburgh: Churchill Livingstone; 2012. p. 880-1.
17. Antiga E, Verdelli A, Bonciani D, Bonciolini V, Quintarelli L, Volpi W, Fabbri P, Caproni M. Drug-induced cutaneous vasculitides. Giornaleitaliano di dermatologia e venereologia: organoufficiale, Societaitaliana di dermatologia e sifilografia. 2015 Apr;150(2):203-10.
18. Anovadiya AP, Barvaliya MJ, Patel TK, Tripathi CB. Cross sensitivity between ciprofloxacin and levofloxacin for an immediate hypersensitivity reaction. Journal of pharmacology &pharmacotherapeutics. 2011 Jul;2(3):187.
19. Seitz CS, Brocker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clinical & Experimental Allergy. 2009 Nov;39(11):1738-45.
20. Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Current Allergy and asthma reports. 2005 Jan 1;5(1):15-21.
21. Mori K, Maru C, Takusuna K. Characterization of Histamine Release Induced by Fluoroquinolone Antibacterial Agents In-
vivo and In-vitro. Journal of pharmacy and pharmacology. 2000 May;52(5):577-84.
22. Ayllón ML, Martínez MG, Mosquera MR, Laguna Martínez JJ, Martíartu MO, Fernandez de Miguel C. Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin. Allergy. 1995 Jul;50(7):598-9.
23. Nakaranurack C. Cross immediate hypersensitivity between ciprofloxacin and levofloxacin: a case report and literature review. Thai Journal of Pharmaceutical Sciences (TJPS). 2016 Jun 27;40(2).
24. Allen GP, Harris KA. In vitro resistance selection in Shigella flexneri by azithromycin, ceftriaxone, ciprofloxacin, levofloxacin, and moxifloxacin. Antimicrobial agents and chemotherapy. 2017 Jul 1;61(7):e00086-17.

Cite this article as:
K S Charitha et al. Ciprofloxacin induced cutaneous vasculitis: A cross reaction to norfloxacin. Int. J. Res. Ayurveda Pharm. 2019;10(3):83-86 http://dx.doi.org/10.7897/2277-4343.100368

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IJRAP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJRAP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IJRAP editor or editorial board members.